首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   15362篇
  免费   1058篇
  国内免费   109篇
耳鼻咽喉   134篇
儿科学   465篇
妇产科学   454篇
基础医学   2414篇
口腔科学   272篇
临床医学   1245篇
内科学   3531篇
皮肤病学   376篇
神经病学   2199篇
特种医学   418篇
外科学   1433篇
综合类   28篇
一般理论   1篇
预防医学   817篇
眼科学   167篇
药学   1093篇
中国医学   32篇
肿瘤学   1450篇
  2023年   189篇
  2022年   168篇
  2021年   527篇
  2020年   395篇
  2019年   480篇
  2018年   634篇
  2017年   471篇
  2016年   518篇
  2015年   593篇
  2014年   731篇
  2013年   968篇
  2012年   1389篇
  2011年   1392篇
  2010年   778篇
  2009年   707篇
  2008年   1167篇
  2007年   1057篇
  2006年   958篇
  2005年   852篇
  2004年   779篇
  2003年   689篇
  2002年   526篇
  2001年   54篇
  2000年   33篇
  1999年   53篇
  1998年   82篇
  1997年   53篇
  1996年   37篇
  1995年   41篇
  1994年   44篇
  1993年   22篇
  1992年   18篇
  1991年   18篇
  1990年   16篇
  1989年   15篇
  1988年   7篇
  1987年   10篇
  1986年   10篇
  1985年   8篇
  1984年   6篇
  1983年   5篇
  1982年   6篇
  1981年   5篇
  1980年   7篇
  1979年   4篇
  1978年   2篇
  1977年   1篇
  1976年   1篇
  1975年   1篇
  1974年   2篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination.  相似文献   
2.
When several Helicobacter pylori eradication treatments fail, guidelines recommend a cultured guided approach; however, culture is not widely available. Therefore, a rifabutin based regimen could be the best solution. Rifabutin indeed shows a low rate of antibiotic resistance. Rifabutin is generally used in combination with amoxicillin in a triple therapy, with eradication rates about 80% in third-line regimens. The ideal duration of this therapy should range between 10 and 12 d. Combinations with antibiotics other than amoxicillin have demonstrated even better results, such as vonoprazan, which is a type of novel acid suppressor drug. Finally, a new formulation of triple therapy in a single capsule is under investigation, which is a field that deserves further investigation. Some notes of caution about rifabutin should be mentioned. This drug is used to treat tuberculosis or atypical mycobacteria; therefore, before starting a rifabutin-based eradication regimen, Mycobacterium tuberculosis infection should be thoroughly tested, since its use could promote the development of antibiotic resistance, thus affecting its effectiveness against Koch’s bacillus. Additionally, some serious side effects must be evaluated before starting any rifabutin-based therapy. Adverse effects include fever, nausea, vomiting and bone marrow suppression. For this reason, full blood count surveillance is required.  相似文献   
3.
Adiponectin is the major adipocytes-secreted protein involved in obesity-related breast cancer growth and progression. We proved that adiponectin promotes proliferation in ERα-positive breast cancer cells, through ERα transactivation and the recruitment of LKB1 as ERα-coactivator. Here, we showed that adiponectin-mediated ERα transactivation enhances E-cadherin expression. Thus, we investigated the molecular mechanism through which ERα/LKB1 complex may modulate the expression of E-cadherin, influencing tumor growth, progression and distant metastasis. We demonstrated that adiponectin increases E-cadherin expression in ERα-positive 2D and higher extent in 3D cultures. This occurs through a direct activation of E-cadherin gene promoter by ERα/LKB1-complex. The impact of E-cadherin on ERα-positive breast cancer cell proliferation comes from the evidence that in the presence of E-cadherin siRNA the proliferative effects of adiponectin is no longer noticeable. Since E-cadherin connects cell polarity and growth, we investigated if the adiponectin-enhanced E-cadherin expression could influence the localization of proteins cooperating in cell polarity, such as LKB1 and Cdc42. Surprisingly, immunofluorescence showed that, in adiponectin-treated MCF-7 cells, LKB1 and Cdc42 mostly colocalize in the nucleus, impairing their cytosolic cooperation in maintaining cell polarity. The orthotopic implantation of MCF-7 cells revealed an enhanced E-cadherin-mediated breast cancer growth induced by adiponectin. Moreover, tail vein injection of MCF-7 cells showed a higher metastatic burden in the lungs of mice receiving adiponectin-treated cells compared to control. From these findings it emerges that adiponectin treatment enhances E-cadherin expression, alters cell polarity and stimulates ERα-positive breast cancer cell growth in vitro and in vivo, sustaining higher distant metastatic burden.  相似文献   
4.
5.
Journal of Assisted Reproduction and Genetics - To study whether a new combination of different warming kits is clinically effective for vitrified human blastocysts. This is a longitudinal cohort...  相似文献   
6.
Clinical Rheumatology - Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. Patients...  相似文献   
7.
European Archives of Psychiatry and Clinical Neuroscience - Difficulties in interpersonal communication, including conversational skill impairments, are core features of schizophrenia. However,...  相似文献   
8.
9.
An experimental probabilistic approach for health risk assessment was applied for graphene nanoplatelets (GNPs). The hazard assessment indicated a low level of toxicity for the GNPs. The benchmark dose method, based on sub-chronic and chronic inhalation exposure studies, was used to quantify a guidance value (BMCh) for occupational inhalation exposure to GNPs, expressed as a lognormal distribution with a geometric mean?±?geometric standard deviation of 0.212?±?7.79?mg/m3 and 9.37?×?104?±?7.6 particle/cm3. Exposure scenarios (ES) were defined based on the scientific literature for large-scale production (ES1) and manufacturing (ES2) of GNPs; a third ES, concerning in-lab handling of GNPs (ES3) was based on results of experiments performed for this study. A probability distribution function was then assumed for each ES. The risk magnitude was calculated using a risk characterization ratio (RCR), defined as the ratio of the exposure distributions and the BMCh distribution. All three ES resulted in RCR distributions ≥1 (i.e. risk present); however, none of the ES had a statistically significant level of risk at a 95% confidence interval. A sensitivity analysis indicated that ~75% of the variation in the RCR distributions was due to uncertainties in the BMCh calculation.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号